Policies of US Companies Offering Direct-to-Consumer Laboratory Tests
JAMA Internal Medicine · 2023
DOI: 10.1001/jamainternmed.2023.4726 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, 2023. Verfasst von Louiza Kalokairinou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Genetic Testing, Informed Consent. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.
Abstract (Originalsprache)
This qualitative study assesses the practices and policies of companies offering direct-to-consumer laboratory testing in the US.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas.
Förderung
- NIH HHS
Zitieren
APA
Kalokairinou, L., Choi, R., Wei, N. Y., & Wexler, A. (2023). Policies of US Companies Offering Direct-to-Consumer Laboratory Tests. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2023.4726
Vancouver
Kalokairinou L, Choi R, Wei NY, Wexler A. Policies of US Companies Offering Direct-to-Consumer Laboratory Tests. JAMA Internal Medicine. 2023. doi:10.1001/jamainternmed.2023.4726
BibTeX
@article{Kalokairinou2023,
author = {Kalokairinou, Louiza and Choi, Rebekah and Wei, Nina Yichen and Wexler, Anna},
title = {Policies of US Companies Offering Direct-to-Consumer Laboratory Tests},
journal = {JAMA Internal Medicine},
year = {2023},
doi = {10.1001/jamainternmed.2023.4726}
}
EUVIMED